Novavax ‘applauds’ President Trump’s call for available COVID-19 vaccine data

Novavax (NVAX) issued the following statement on publicly available COVID-19 vaccine data: “Novavax is a U.S.-based biotechnology company that is proud to have successfully developed a COVID-19 vaccine as part of President Trump’s Operation Warp Speed. Under President Trump’s leadership, this program enabled the ingenuity of the American scientific community to come together to solve the most pressing public health issue of our lifetime. For Novavax, this resulted in the development of the only non-mRNA, protein-based COVID-19 vaccine available in the U.S. and many markets around the world. We applaud President Trump’s call for available data, and consistent with that, we have shared clinical and preclinical data, and real-world evidence for Novavax’s COVID-19 vaccine via publication, at medical meetings, on our website and/or via press release. Additionally, we have made these data available to the U.S. Food and Drug Administration, the U.S. Centers for Disease Control and Prevention, dozens of regulatory bodies around the world and scientific and medical experts in public health. A list of publicly available information is at the link here and we will continue to add additional information here. Novavax’s COVID-19 vaccine is based on a well-established, protein-based technology platform that includes our proprietary Matrix-M adjuvant. Through Operation Warp Speed and President Trump’s leadership, Americans have been given an important tool to protect themselves and ensure that they have choice in doing so.”